Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ascorbate and Radiation in Soft Tissue Sarcomas
NCT03508726Phase 2Completed
- Start
- Jun 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ascorbic acid in soft tissue sarcoma (STS) (2 cohorts). Primary endpoints: Dose Limiting Toxicities and Pathologic Tumor Necrosis >= 95%. Started Jun 2019; status: completed.
02
Drugs
ascorbic acid
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03508726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03508726.